Page 14 - Sci Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ... Avadel Pharmaceuticals plcApril 17, 2021 GMT Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium o...

Press release content from Accesswire. The AP news staff was not involved in its creation. 9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update March 15, 2021 GMT Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, ...

- Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biopharma

(1) RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patrick Griffin, M.D., FACP, will participate in an invited presentation at an upcoming virtual workshop entitled Accelerating Progress in Celiac Disease. The workshop is a National Institutes of Health workshop co-sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), to be held on March 18-1...

Share this article HOLON, Israel, March 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis" reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Joh...